Navigation Links
Herding cancer cells to their death
Date:6/20/2013

June 20, 2013, New York, NY and Oxford, UK An advanced tumor is a complex ecosystem. Though derived from a single cell, it evolves as it grows until it contains several subspecies of cells that vary dramatically in their genetic traits and behaviors. This cellular heterogeneity is what makes advanced tumors so difficult to treat. Publishing their findings in today's online issue of Cancer Cell, an international team of scientists led jointly by Professors Colin Goding from the Ludwig Institute for Cancer Research who is based at the University of Oxford and Jos Neptuno Rodriguez-Lpez from the University of Murcia, Spain describe a therapeutic strategy that manipulates a mechanism driving that heterogeneity to treat advanced melanoma. Their preclinical studies show that the strategy, which employs a new drug-like molecule in combination with an existing chemotherapy, is highly specific to melanoma cells and effective against tumors that resist all other therapies.

If caught early, melanoma is relatively easy to treat. But in its late stages, it is a stubborn and deadly cancer. Until about a decade ago, patients survived only about seven months after starting treatment. Since then, therapies, such as vemurafenib, that specifically target signaling proteins essential to the proliferation and survival of melanoma cells have extended the lives of some patients. But only about half respond to these targeted therapies, and even in those patients the cancer begins to resist the targeted therapy within six to nine months.

To bypass such resistance, the researchers developed a strategy that essentially pushes subtypes of melanoma cells that are not dividingand are therefore not susceptible to chemotherapyto become vulnerable to a shrewdly targeted drug.

To develop their therapy, the scientists first screened a variety of molecules to find one that boosts the expression of MITF, a master gene that, at high levels, pushes melanoma cells to proliferate and to express a protein known as Tyrosinase that fuels pigment production. The scientists found that methotrexatea drug currently used to treat autoimmune diseases and some other cancers, though not melanomahad precisely that effect. The Spanish team then synthesized a novel molecule called TMECG that is lethal only when it is chemically modified by Tyrosinase. When activated by Tyrosinase, TMECG disrupts the protein machinery of cell division and so poisons cells that are multiplying rapidly.

"The beauty of the therapy," says Professor Jos Neptuno Rodriguez-Lpez, PhD, leader of the Spanish team at the University of Murcia, is that "TMECG is activated by a process that is specific to pigmented cells but not other cells. So, first the methotrexate sensitizes melanoma cells to the effects of TMECG. Then that molecule gets processed and activated by Tyrosinase to form an active compound that kills rapidly dividing cells. Even better, the methotrexate then delivers a second blow to melanoma cells by prompting them to commit suicide through a very specific mechanism."

The researchers found that the combined treatment efficiently destroyed melanoma cells in culture, even those derived from patient tumors resistant to vemurafenib and other targeted melanoma therapies. It also significantly suppressed tumors in one mouse model and diminished metastases in another.

In mice, the treatment combination does not appear to injure other pigmented cells, such as healthy cells of the skin, or those of the iris or the retina, probably because those cells are not rapidly proliferating. The researchers are now refining their new drug to improve its pharmacologic profile and figure out how to deliver it to the right places in the body.

"Think about what you ideally want from a cancer therapy," says Professor Colin Goding, PhD, Member of the Ludwig Institute for Cancer Research who is based at the University of Oxford. "You want a therapy that addresses cancer cell heterogeneity, that eradicates the tendency of cancer cells to become invasive, that works on cells that are resistant to other therapies and that targets only the cancer cells and not any others. I think we've ticked all those boxes."

"By inducing melanoma to differentiate using an old chemotherapy drug, Saez-Ayala and colleagues took advantage of a protein expressed at high levels as a consequence of that differentiation to turn a molecule they have designed into a prolific melanoma killer," said Antoni Ribas, MD, PhD, Professor of Medicine at the University of California Los Angeles and the Jonsson Comprehensive Cancer Center in Los Angeles. "Based on their preclinical data, I believe that this two-step approach may have promise for treating melanoma."

Still, Goding notes, cancer cells are so mutable that some melanoma cells will inevitably develop resistance to the novel therapy. So he expects that, aside from showing that the strategy works in patients, future research will have to show that it can be combined with other cancer therapies to get around such resistance. "That's how we should be thinking about cancer therapy," he says. "The complexity of the disease is such that any one therapy probably won't work on its own. But if you give complementary therapies that work in completely different ways, then I think you have a chance against this disease."


'/>"/>

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Related biology news :

1. No danger of cancer through gene therapy virus
2. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
3. Osteoporosis drug stops growth of breast cancer cells, even in resistant tumors
4. Using math to kill cancer cells
5. Gene variants may predict who will benefit from breast cancer prevention drugs
6. Nanotechnology helps track and improve drug action in pancreatic cancer
7. Biomarker identification may lead to new noninvasive test for colorectal cancer detection
8. First dual-action compound kills cancer cells, stops them from spreading
9. New Research: Modified Citrus Pectin - A Potent Anti-Cancer Therapy
10. U of A medical researchers ID genetic marker for sporadic breast cancer
11. Modulating the immune system to combat metastatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/11/2016)... SAN JOSE, Calif. , Jan. 11, 2016 /PRNewswire/ ... developer of human interface solutions, today announced that its ... display driver integration (TDDI) products won two separate categories ... including Best Mobile Innovator and Best Technology Breakthrough. The ... overall system cost, a simplified supply chain, thinner devices, ...
(Date:1/7/2016)... Various factors have contributed to the ... biologics and biosimilars. Some of these factors include ... demand for cost-effective alternatives, growing burden of chronic ... versions of their corresponding patented biologic drugs, and ... and efficacy. The global biosimilars market is estimated ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... HILL, N.C. , Feb. 5, 2016  In ... key role for a host of launch activities including ... importance of this launch activity is especially high in ... specialists. Best Practices and the Role of ... will help companies focused on oncology therapies find better ...
(Date:2/4/2016)... Massachusetts , February 4, 2016 - New FDA ... - New FDA action date of July 22, ... of July 22, 2016   - ... U.S. in the past decade indicated for the treatment of signs and symptoms ... Lifitegrast has the potential to be the only product approved in the U.S. ...
(Date:2/4/2016)... Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... its flagship CytoSorb® blood filter to treat deadly ... the world, announced that CEO Dr. Phillip ... Source Capital Group,s 2016 Disruptive Growth & Healthcare ... company.  Conference Presentation Details: ...
(Date:2/4/2016)... -- Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... in China , today announced that ... on February 4, 2016 a preliminary non-binding proposal letter, ... PKU V-Ming ( Shanghai ) Investment Holdings ... ( Shenzhen ) Fund Management Co., Ltd., ...
Breaking Biology Technology: